🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT04547673
Recruiting Observational

To Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal Carcinoma

NCT04547673 · tracked via the Priya Life Science China tracker
Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Phase
Observational
Started
2020-06-20
Last updated
2024-02-20

Condition(s) studied

Otolaryngological DiseaseArtificial Intelligence

Investigational drug(s) / intervention(s)

rigid nasal endoscopes

rigid nasal endoscopes: The endoscope is introduced through the nasal passage to observe, in sequence, the posterior nostril, superior and posterior walls of the nasopharynx, torus tubarius, pharyngeal opening of the auditory tube, and Rosenmu¨ller recess. The imaging light mode is set to conventional WLI and subsequently switch to NBI during the procedure, and representative images are collected and preserve for further analysis. All lesions, detected by either WLI or NBI, are biopsied.

Study summary

Nasopharyngeal carcinoma (NPC) occurs at a high frequency in southern China, northern Africa, and Alaska, with a reported incidence of 30 cases per 100 000 in Guangdong Province. Endoscopic examination and biopsy are the main methods used for detection and diagnosis of NPC. Early NPC patients achieve favourable prognoses after concurrent radiotherapy and chemotherapy in compassion with advanced NPC patients.

Here, the investigators focused on the utility of artificial intelligence to detect early NPC, which based on white light imaging (WLI) and Narrow-band imaging (NBI) nasoendoscopic examination. Having access to this unique population provides an unprecedented opportunity to investigate the effect of intelligent system on diverse nasopharyngeal lesions detection and develop a novel Computer-Aided Diagnosis System.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Older than 18 years of age Exclusion Criteria: * Refuse to sign the informed consent statement * Patients who have contraindications, e.g. coagulation dysfunction, drug allergy.

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
First Affiliated Hospital of Sun Yat-sen University Guangzhou Guangdong Recruiting
Sun Yat-Sen University Cancer Center Guangzhou Guangdong Recruiting
Kiang Wu Hospital Macao Macao Recruiting

More First Affiliated Hospital, Sun Yat-Sen University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04547673 on ClinicalTrials.gov ↗ ← All trials in China